Zura Bio Limited (ZURA) 10-Year Financial Performance & Capital Metrics

ZURA • • Industrial / General

HealthcareBiotechnologyAutoimmune & Inflammatory DiseasesDermatology & Autoimmune

AboutZura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops ZB-168, an anti IL7R a inhibitor that impact on diseases driven by IL7 and TSLP biological pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in San Diego, California.Show more

Revenue $0
EBITDA -$55M +11.9%
Net Income -$52M +13.2%
EPS (Diluted) -0.60 +71.3%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -43.75% +79.2%
ROIC -
Debt/Equity -
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 97 (top 3%)

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Shares diluted 100.0% in last year
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-32.31%

EPS CAGR

10Y-

5Y-

3Y-

TTM-26.28%

ROCE

10Y Avg-66.18%

5Y Avg-66.18%

3Y Avg-87.97%

Latest-45.88%

Peer Comparison

Dermatology & Autoimmune

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
AUPHAurinia Pharmaceuticals Inc.	1.96B	14.87	378.37	33.97%	29.28%	21.28%	2.25%	0.21
ARGXargenx SE	50.33B	813.24	63.63	78.6%	23.34%	15.14%		0.01
INVAInnoviva, Inc.	1.48B	19.76	54.89	15.54%	32.78%	12.61%	12.75%	0.65
GLPGGalapagos N.V.	2.24B	34.03	30.38	14.99%	-151.94%	-15.16%		0.00
PTGXProtagonist Therapeutics, Inc.	5.3B	84.75	20.04	6.24%	21.94%	7.11%	3.45%	0.02
ALMSAlumis Inc. Common Stock	2.84B	24.17	-2.33		-11.08%	-63.71%		0.12
PHATPhathom Pharmaceuticals, Inc.	1.17B	14.98	-2.83	80.01%	-186.53%
ORKAOruka Therapeutics, Inc.	1.57B	32.50	-6.51			-22.44%		0.00

Profit & Loss

	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0
Revenue Growth %	-	-	-	-
Cost of Goods Sold+	0	0	0	0
COGS % of Revenue	-	-	-	-
Gross Profit+	0	0	0	0
Gross Margin %	-	-	-	-
Gross Profit Growth %	-	-	-	-
Operating Expenses+	1.09M	27.16M	62.64M	55.19M
OpEx % of Revenue	-	-	-	-
Selling, General & Admin	1.09M	3.47M	18.64M	30.79M
SG&A % of Revenue	-	-	-	-
Research & Development	0	23.69M	44M	24.4M
R&D % of Revenue	-	-	-	-
Other Operating Expenses	0	0	0	0
Operating Income+	-1.09M	-27.16M	-62.64M	-55.19M
Operating Margin %	-	-	-	-
Operating Income Growth %	-	-23.87%	-1.31%	0.12%
EBITDA+	8.42M	-27.16M	-62.64M	-55.18M
EBITDA Margin %	-	-	-	-
EBITDA Growth %	-	-4.23%	-1.31%	0.12%
D&A (Non-Cash Add-back)	0	0	0	9K
EBIT	8.42M	-27.16M	-62.64M	-55.19M
Net Interest Income+	23.48K	570	2.19M	8M
Interest Income	23.48K	570	2.19M	8M
Interest Expense	0	0	0	0
Other Income/Expense	9.51M	-171K	2.08M	2.79M
Pretax Income+	8.42M	-27.33M	-60.56M	-52.4M
Pretax Margin %	-	-	-	-
Income Tax+	0	0	0	0
Effective Tax Rate %	1%	0.94%	1%	1%
Net Income+	8.42M	-25.74M	-60.36M	-52.4M
Net Margin %	-	-	-	-
Net Income Growth %	-	-4.06%	-1.35%	0.13%
Net Income (Continuing)	8.42M	-27.33M	-60.56M	-52.4M
Discontinued Operations	0	0	0	0
Minority Interest	0	10M	20.22M	13.2M
EPS (Diluted)+	0.40	0.21	-2.09	-0.60
EPS Growth %	-	-0.47%	-10.95%	0.71%
EPS (Basic)	0.40	0.21	-2.09	-0.60
Diluted Shares Outstanding	17.25M	17.25M	33.06M	75.07M
Basic Shares Outstanding	17.25M	17.25M	33.06M	75.07M
Dividend Payout Ratio	-	-	-	-

Balance Sheet

	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	1.15M	1.78M	100.84M	178.74M
Cash & Short-Term Investments	729.22K	1.57M	99.81M	176.5M
Cash Only	729.22K	1.57M	99.81M	176.5M
Short-Term Investments	0	0	0	0
Accounts Receivable	0	0	0	0
Days Sales Outstanding	-	-	-	-
Inventory	0	0	0	0
Days Inventory Outstanding	-	-	-	-
Other Current Assets	0	189.3K	1.04M	2.25M
Total Non-Current Assets+	139.4M	3.49M	0	789K
Property, Plant & Equipment	0	0	0	91K
Fixed Asset Turnover	-	-	-	-
Goodwill	0	0	0	0
Intangible Assets	0	0	0	0
Long-Term Investments	139.4M	0	0	0
Other Non-Current Assets	0	3.49M	0	698K
Total Assets+	140.55M	5.26M	100.84M	179.53M
Asset Turnover	-	-	-	-
Asset Growth %	-	-0.96%	18.16%	0.78%
Total Current Liabilities+	272.29K	14.82M	20.3M	19.51M
Accounts Payable	0	2.01M	2.75M	733K
Days Payables Outstanding	-	-	-	-
Short-Term Debt	0	7.76M	0	0
Deferred Revenue (Current)	0	0	0	0
Other Current Liabilities	272.29K	2.77M	1.2M	18.78M
Current Ratio	4.23x	0.12x	4.97x	9.16x
Quick Ratio	4.23x	0.12x	4.97x	9.16x
Cash Conversion Cycle	-	-	-	-
Total Non-Current Liabilities+	10.08M	12.5M	990K	0
Long-Term Debt	0	0	0	0
Capital Lease Obligations	0	0	0	0
Deferred Tax Liabilities	0	0	0	0
Other Non-Current Liabilities	10.08M	12.5M	990K	0
Total Liabilities	10.35M	27.32M	21.29M	19.51M
Total Debt+	0	7.76M	0	0
Net Debt	-729.22K	6.19M	-99.81M	-176.5M
Debt / Equity	-	-	-	-
Debt / EBITDA	-	-	-	-
Net Debt / EBITDA	-0.09x	-	-	-
Interest Coverage	-	-	-	-
Total Equity+	130.2M	-22.06M	79.55M	160.02M
Equity Growth %	-	-1.17%	4.61%	1.01%
Book Value per Share	7.55	-1.28	2.41	2.13
Total Shareholders' Equity	130.2M	-32.06M	59.33M	146.81M
Common Stock	139.38M	0	4K	7K
Retained Earnings	-9.18M	-32.06M	-103.49M	-155.9M
Treasury Stock	0	0	0	0
Accumulated OCI	0	0	0	0
Minority Interest	0	10M	20.22M	13.2M

Cash Flow

	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-1.1M	-1.2M	-15.05M	-28.08M
Operating CF Margin %	-	-	-	-
Operating CF Growth %	-	-0.09%	-11.52%	-0.87%
Net Income	8.42M	-27.33M	-60.56M	-52.4M
Depreciation & Amortization	0	0	0	9K
Stock-Based Compensation	0	334K	9.65M	16.8M
Deferred Taxes	0	0	0	0
Other Non-Cash Items	-9.28M	22.26M	30.74M	5.21M
Working Capital Changes	-235.6K	3.54M	5.12M	2.31M
Change in Receivables	2.87K	0	0	0
Change in Inventory	0	0	0	0
Change in Payables	0	288.29K	0	4.21M
Cash from Investing+	-139.38M	-12M	-8M	-5.08M
Capital Expenditures	0	-12M	-8M	-75K
CapEx % of Revenue	-	-	-	-
Acquisitions	-	-	-	-
Investments	-	-	-	-
Other Investing	0	0	0	-5M
Cash from Financing+	141.21M	14.77M	121.29M	109.84M
Debt Issued (Net)	-	-	-	-
Equity Issued (Net)	-	-	-	-
Dividends Paid	0	0	0	0
Share Repurchases	-	-	-	-
Other Financing	505K	-2.83M	14.89M	49.09M
Net Change in Cash	-	-	-	-
Free Cash Flow+	-1.1M	-13.2M	-23.05M	-28.15M
FCF Margin %	-	-	-	-
FCF Growth %	-	-11.02%	-0.75%	-0.22%
FCF per Share	-0.06	-0.77	-0.70	-0.37
FCF Conversion (FCF/Net Income)	-0.13x	0.05x	0.25x	0.54x
Interest Paid	0	0	0	0
Taxes Paid	0	0	0	0

Key Ratios

Metric	2021	2022	2023	2024
Return on Equity (ROE)	6.46%	-47.6%	-209.97%	-43.75%
Return on Invested Capital (ROIC)	-	-35.86%	-	-
FCF Conversion	-0.13x	0.05x	0.25x	0.54x

Frequently Asked Questions

Growth & Financials

Zura Bio Limited (ZURA) grew revenue by 0.0% over the past year. Growth has been modest.

Zura Bio Limited (ZURA) reported a net loss of $62.5M for fiscal year 2024.

Dividend & Returns

Zura Bio Limited (ZURA) has a return on equity (ROE) of -43.7%. Negative ROE indicates the company is unprofitable.

Zura Bio Limited (ZURA) had negative free cash flow of $53.5M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener